The synergism of ERK1/2 inhibition with MCL-1i has also been reported in melanoma, in which AZD5991 synergized with ERK inhibition and delayed the development of BRAFi/MEKi resistance, thereby improving “the efficacy of an ERK1/2 inhibitor in a model of acquired BRAFi + MEKi resistance” (128). This evidence concerns the gene MAPK3 and melanoma.